|Year : 2016 | Volume
| Issue : 2 | Page : 543-549
Association between fibroblast growth factor receptor-2 gene polymorphism and risk of breast cancer in Chinese populations: A HuGE review and meta-analysis
Yong-Bin Yang1, Zhan-Xue Zhao2, Wei Huang2, Hui Liu1, Yan-Li Tan1, Wei-Ming Wang3
1 Department of Pathology, Health Science Center, Hebei University, Baoding, People's Republic of China
2 Library, Hebei University, Baoding, People's Republic of China
3 Department of Obstetrics and Gynecology, Affiliated Hospital of Hebei University, Baoding, People's Republic of China
|Date of Web Publication||25-Jul-2016|
Department of Obstetrics and Gynecology, Affiliated Hospital of Hebei University, No. 212 Yuhuadonglu, Baoding-071 000
People's Republic of China
Source of Support: This work was supported by the grants from
the Hebei University, Administration of Traditional Chinese Medicine of
Hebei Province, Research Center for Eco-Environmental Sciences of the
Chinese Academy of Sciences (Nos. 2012A1002, 2011213, KF2010-17,
2011107, and 2008071), and the Departments of Science and
Technology of Baoding city and Hebei Province(Nos.13ZF019 and
132777163), and Natural Science Foundation of Hebei Province, China
(grant: H2012201136)., Conflict of Interest: None
Aim of study: To evaluate the effect of fibroblast growth factor receptor.2. (FGFR2) on genetic susceptibility for breast cancer. (BC) in Chinese populations.
Materials and Methods: A computerized literature search was carried out in PubMed, Chinese Biomedical Database. (CBM), and Chinese National Knowledge Infrastructure. (CNKI) to collect relevant articles. Pooled odds ratio. (OR) and 95% confidence interval. (CI) were used to assess the strength of the associations.
Results: A total of 21 articles involving a total of 15 polymorphisms of the FGFR2 gene were included in the meta-analysis. Due to the limited studies for rs17102287, rs2981578, rs3135718, rs3803662, rs3750817, rsl0510097, rsl7542768, rs13387042, and rs1982073; we only pooled the six polymorphisms. (rs11200014, rs1219648, rs2420946, rs2912778, rs2981579, and rs2981582) into this meta.analysis. Overall, significantly increased BC risk was associated with five polymorphisms. (rs2981579, rs2981582, rs1219648, rs2420946, and rs2912778) when all studies were pooled into the meta.analysis. When stratified by ethnicity and source of controls, similar results were also detected. However, for rs2981579 no significant association was found among Chinese Han in all genetic models.
Conclusion: Our meta-analysis suggests that FGFR2 is likely an important genetic marker contributing to susceptibility of BC. We recommend that these single nucleotide polymorphisms to be included in future association studies and functional assays.
Keywords: Breast cancer, Chinese, FGFR2, meta.analysis, polymorphism
|How to cite this article:|
Yang YB, Zhao ZX, Huang W, Liu H, Tan YL, Wang WM. Association between fibroblast growth factor receptor-2 gene polymorphism and risk of breast cancer in Chinese populations: A HuGE review and meta-analysis. J Can Res Ther 2016;12:543-9
|How to cite this URL:|
Yang YB, Zhao ZX, Huang W, Liu H, Tan YL, Wang WM. Association between fibroblast growth factor receptor-2 gene polymorphism and risk of breast cancer in Chinese populations: A HuGE review and meta-analysis. J Can Res Ther [serial online] 2016 [cited 2020 Jul 7];12:543-9. Available from: http://www.cancerjournal.net/text.asp?2016/12/2/543/148715
| > Introduction|| |
Breast cancer (BC) is the most frequently diagnosed cancer and the leading cause of cancer death in females worldwide, accounting for 23% (1.38 million) of the total new cancer cases and 14% (458,400) of the total cancer deaths in 2008. The age-standardized incidence and mortality rates of BC in China in 2008 were 31.71 per 100,000 and 6.48 per 100,000, respectively. It also shows a continuously increasing trend in morbidity of BC in China over recent years., In general, BC etiologic heterogeneity can be attributed to genetic and nongenetic risk factors. However, the association between genetic factors and BC receives more and more attention in recent studies.
Genome-wide association studies (GWAS) have identified multiple genetic variants associated with BC, including fibroblast growth factor receptor-2 (FGFR2). FGFR2 gene, one of the common low-penetrant genes, has been identified as a potential BC susceptibility gene, which encodes a tyrosine kinase receptor that is a member of the family of individually distinct FGFRs involved in tumorigenesis. FGFR2 is amplified and overexpressed in BC,,, and data suggest that FGFR2 is a tumor suppressor gene in prostate cancer and urothelial cancer. Some publications ,,,,,, have reported the role of FGFR2 polymorphism in BC risk, but provided controversial or inconclusive results. In order to lessen the impact of different genetic background, we performed this meta-analysis to assess the relationship of FGFR2 gene polymorphism with risk of BC in Chinese populations.
| > Materials and Methods|| |
A computerized literature search was carried out in PubMed, Embase, Springer Link, Ovid, Chinese Biomedical Database (CBM), Chinese Wanfang Database, and Chinese National Knowledge Infrastructure (CNKI) to collect articles of case–control studies on associations between FGFR2 polymorphism and susceptibility to BC before 18 March 2014. References of the retrieved articles were also screened for original studies. The search strategy involved exploring 'FGFR2' or 'fibroblast growth factor receptor 2' combined with 'breast cancer'. The PubMed search was run using the terms: (FGFR2 [All Fields] OR “fibroblast growth factor receptor 2”[All Fields]) AND “breast cancer”[All Fields] AND (“China”[All Fields] OR “Chinese”[All Fields]).
Eligible studies had to meet all of the following criteria: (1) Case–control study or cohort study studying on associations between FGFR2 gene and BC susceptibility; (2) the diagnosis of BC patients was confirmed histologically or pathologically; (3) sufficient published data about sample size, odds ratio (OR), and their 95% confidence interval (CI); and (4) all participants were Chinese. Studies were excluded when they were: (1) Not case–control study or cohort study; (2) duplicate of previous publication; (3) based on incomplete data; (4) meta-analyses, letters, reviews, or editorial articles.
For each study, the following data were extracted independently by two authors: Authors, years of publication, geographical location of participants, source of controls, numbers of cases and controls, genotype frequencies, and Hardy–Weinberg equilibrium (HWE) test. The results were compared and disagreements were discussed and resolved with consensus. The categorization of ethnicity comprised Han and other ethnic Chinese. Studies with different ethnic groups were considered as individual studies for our analyses.
Pooled ORs and 95% CIs were used to assess the strength of the associations. Pooled ORs and 95% CIs for all studies combined were calculated. Furthermore, subgroup analyses were performed by ethnicity and sources of controls. Chi-square test was used for HWE of genotypes in control group of each reviewed study. Statistical heterogeneity among studies was assessed with the Q-statistics. Dependent on the results of heterogeneity test among individual studies, the fixed effect model (Mantel–Haenszel) or random effect model (DerSimonian and Laird) was selected to summarize the combined OR. The significance of the pooled OR was determined by the z-test. Publication bias was investigated with the funnel plot, in which the standard error (SE) of log OR of each study was plotted against its OR. Funnel-plot asymmetry was further assessed by the method of Egger's linear regression test. Analyses were performed using the software Stata version 10.0 (Stata Corp, College Station, Texas, USA). All the P values were two sided. P value less than 0.05 was considered statistically significant.
| > Results|| |
Characteristics of studies
The combined search yielded 56 references. Study selection process has been shown in [Figure 1]. A total of 21 articles ,,,,,,,,,,,,,,,,,,,, were finally included in this meta-analysis. Of which, four studies included 1,799 BC cases and 2,075 controls were conducted for rs11200014; 11 studies included 6.130 cases and 6,218 controls for rs2981582; and 3 studies included 760 cases and 760 controls for rs2912778. Eight studies were available for the rs2420946 with 2,636 cases and 2,756 controls, for rs1219648 with 4,121 cases and 4,497 controls, and for rs2981579 with 2,548 cases and 2,906 controls, respectively. For the rs17102287, rs2981578, rs3135718, and rs3803662 polymorphism; two studies each were included. There was only one study for rs3750817, rsl0510097, rsl7542768, rs13387042, and rs1982073. The detailed characteristics of the included studies are shown in [Table 1].
Association of rs11200014 polymorphism with BC
Significant heterogeneity was present among the included studies (P < 0.05). Using random effect model, there were no significant associations under any models in overall and subgroup analyses [Table 2].
|Table 2: Meta-analysis of the FGFR2 rs11200014 polymorphism on breast cancer risk|
Click here to view
Association of rs1219648 polymorphism with BC
Overall, the per-allele OR of the rs1219648 polymorphism for BC was 1.20 (95% CI 1.13–1.28) with corresponding results under dominant, recessive, homozygous, and heterozygous genetic models of 1.20 (95% CI 1.01–1.41), 1.30 (95% CI 1.16–1.45), 1.43 (95% CI 1.26–1.62), and 1.21 (95% CI 1.08–1.37), respectively. In the stratified analysis by ethnicity and source of controls, significantly increased risks were also found [Table 3].
|Table 3: Meta-analysis of the FGFR2 rs1219648 polymorphism on breast cancer risk|
Click here to view
Association of rs2420946 polymorphism with BC
In the overall analysis, the risk allele of rs2420946 was significantly associated with elevated BC (OR = 1.15, 95% CI 1.06–1.24). Significant associations were also found under dominant (OR = 1.24; 95% CI 1.11–1.39) and homozygous genetic models (OR = 1.31; 95% CI 1.12–1.54) [Table 4]. When studies were stratified for source of controls, significant risks were found among hospital-based studies in allele and dominant genetic models, while only in dominant model for population-based studies. In the stratified analysis by ethnicity, significant associations were also detected in Chinese Han under allele and dominant genetic models.
|Table 4: Meta-analysis of the FGFR2 rs2420946 polymorphism on breast cancer risk|
Click here to view
Association of rs2912778 polymorphism with BC
Three studies were all population-based, and no one mentioned the ethnicity. Under allele model, the per-allele overall OR of the T variant for BC was 1.20 (95% CI 1.04–1.39). However, we failed to detect any association to BC risk in other genetic models (dominant model, OR = 3.72, 95% CI 0.88–15.62; recessive model, OR = 0.74, 95% CI 0.45–1.22; homozygous model, OR = 2.22; 95% CI 0.84–5.89; and heterozygous model, OR = 0.49, 95% CI 0.22–1.06).
Association of rs2981579 polymorphism with BC
Significant associations were detected in all genetic models for overall analyses (allele model, OR = 1.17, 95% CI 1.09–1.27; dominant model, OR = 1.21, 95% CI 1.08–1.36; recessive model, OR = 1.26, 95% CI 1.11-1.43; homozygous model, OR = 1.37, 95% CI 1.18–1.59; and heterozygous model, OR = 1.20, 95% CI 1.05–1.37). When studies were stratified for ethnicity and source of controls, significant risks were also found among population-based studies and Chinese not mentioned ethnicity in all genetic models [Table 5].
|Table 5: Meta-analysis of the FGFR2 rs2981579 polymorphism on breast cancer risk|
Click here to view
Association of rs2981582 polymorphism with BC
In overall analyses, the significant increased risks were found under the allele, dominant, recessive, and homozygous models (allele model, OR = 1.20, 95% CI 1.13–1.26; dominant model, OR = 1.27, 95% CI 1.18–1.36; recessive model, OR = 1.24, 95% CI 1.05–1.45; and homozygous model, OR = 1.38, 95% CI 1.22–1.55). Similar results were also detected in the subgroup analysis [Table 6].
|Table 6: Meta-analysis of the FGFR2 rs2981582 polymorphism on breast cancer risk|
Click here to view
In order to compare the difference and evaluate the sensitivity of the meta-analyses, we used both models (the fixed effect and random effect model) to evaluate the stability of the meta-analysis. The results of allele models for rs2912778 in overall analysis, for rs2420946 in hospital-based studies and Chinese Han were altered, as well as recessive and heterozygous models for rs1219648 in hospital-based studies (data not shown). All the other results were not materially altered. Hence, results of the sensitivity analysis suggest that the data in this meta-analysis are relatively stable and credible.
The Begg's funnel plot and Egger's test were performed to assess the publication bias of literatures. The shape of the funnel plots did not reveal obvious asymmetry. Then, the Egger's test was used to provide statistical evidence of funnel plot symmetry. The statistical results still did not show publication bias in allele model of overall analysis for rs11200014 (t = 0.60, P = 0.607), rs1219648 (t = −0.54, P = 0.609), rs2420946 (t = 0.40, P = 0.704), rs2912778 (t = −0.23, P = 0.858), rs2981579 (t = −0.69, P = 0.513), and rs2981582 (t = −0.17, P = 0.867).
| > Discussion|| |
Large sample and unbiased epidemiological studies of predisposition genes polymorphisms could provide insight into the in vivo relationship between candidate genes and diseases. This is the first most comprehensive meta-analysis examining the FGFR2 polymorphisms and the risk of BC in Chinese populations, which will be helpful in providing a new insight of gene polymorphisms in BC development. Its strength was based on the accumulation of published data concerning Chinese to detect significant differences. In total, the meta-analysis involved 21 articles for BC which included 15 polymorphisms in FGFR2 gene (rs11200014, rs1219648, rs2420946, rs2912778, rs2981579, rs2981582, rs17102287, rs2981578, rs3135718, rs3803662, rs3750817, rsl0510097, rsl7542768, rs13387042, and rs1982073). Due to the limited studies for rs17102287, rs2981578, rs3135718, rs3803662, rs3750817, rsl0510097, rsl7542768, rs13387042, and rs1982073; we only pooled the other six polymorphisms (rs11200014, rs1219648, rs2420946, rs2912778, rs2981579, and rs2981582) into this meta-analysis.
Our results demonstrated that the rs2981579, rs2981582, rs1219648, rs2420946, and rs2912778 polymorphisms of FGFR2 are risk factors for developing BC. For rs2912778, the significant association was only detected in the allele model. Considering the limited sample size and sensitivity analysis, the result for rs2912778 should be interpreted with cautions. In the stratified analysis by ethnicity, significant associations were observed both in Chinese Han and others in some genetic models for rs1219648 and rs2981582, suggesting a similar role of these polymorphisms in different Chinese ethnicity with different genetic backgrounds and living environment. However, no associations were found in Chinese Han population for rs2981579. In the stratified analysis according to source of controls, significantly increased BC susceptibility in FGFR2 risk allele carriers were also found among population-based and hospital-based controls for rs1219648, rs2420946, and rs2981582. The results were consistent with previously published meta-analyses,,,, which showed an increased risk of BC associated with rs2981582, rs1219648, rs2981579, and rs2420946 polymorphisms among Asians. However, these previously published meta-analyses included a smaller number of polymorphisms in FGFR2 gene, and they did not calculate pooled ORs for studies in Chinese populations.
In interpreting the results, the main limitations of the study should be considered. Firstly, lack of original data of the reviewed studies limited our further evaluation of potential interactions, because the interactions between gene-to-gene, gene-to-environment, and even different polymorphic loci of the same gene may modulate cancer risk. Secondly, because some relevant published and unpublished studies which were likely to have null results were not included, a possible bias, especially the outcome-reporting bias, could not be ruled out, although the result for publication bias was not statistically significant. Thirdly, the conclusions for rs17102287, rs2981578, rs3135718, rs3803662, rs3750817, rsl0510097, rsl7542768, rs13387042, and rs1982073 cannot be drawn because of the relevant small sample size.
In conclusion, our meta-analysis indicates that five functional polymorphisms (rs2981579, rs2981582, rs1219648, rs2420946, and rs2912778) in the promoter of FGFR2 gene are associated with BC susceptibility in Chinese populations and might be potential biomarkers for BC risk. However, larger well-designed studies with subjects of the same ethnic background and tissue-specific biochemical and biological characteristics are required to validate these findings. Moreover, gene–gene and gene–environment interactions should also be considered in the future analysis.
| > References|| |
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
Chen WQ, Zheng RS, Zeng HM, Zhang SW, Li GL, Wu LY, et al
. Incidence and mortality of breast cancer in China, 2008. Thorac Cancer 2013;4:59-65.
Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, et al
. Associations of breast cancer risk factors with tumor subtypes: A pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 2011;103:250-63.
Moffa AB, Tannheimer SL, Ethier SP. Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. Mol Cancer Res 2004;2:643-52.
Grose R, Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 2005;16:179-86.
Moffa AB, Ethier SP. Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells. J Cell Physiol 2007;210:720-31.
Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005;16:139-49.
Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al
. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447:1087-93.
Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, et al
. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007;39:870-4.
Raskin L, Pinchev M, Arad C, Lejbkowicz F, Tamir A, Rennert HS, et al
. FGFR2 is a breast cancer susceptibility gene in Jewish and Arab Israeli populations. Cancer Epidemiol Biomarkers Prev 2008;17:1060-5.
Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, et al
. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 2008;4:e1000054.
Boyarskikh UA, Zarubina NA, Biltueva JA, Sinkina TV, Voronina EN, Lazarev AF, et al
. Association of FGFR2 gene polymorphisms with the risk of breast cancer in population of West Siberia. Eur J Hum Genet 2009;17:1688-91.
Kawase T, Matsuo K, Suzuki T, Hiraki A, Watanabe M, Iwata H, et al
. FGFR2 intronic polymorphisms interact with reproductive risk factors of breast cancer: Results of a case control study in Japan. Int J Cancer 2009;125:1946-52.
Mcinerney N, Colleran G, Rowan A, Walther A, Barclay E, Spain S, et al
. Low penetrance breast cancer predisposition SNPs are site specific. Breast Cancer Res Treat 2009;117:151-9.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
Cen YL, Qi ML, Li HG, Su Y, Chen LJ, Lin Y, et al
. Associations of polymorphisms in the genes of FGFR2, FGF1, and RBFOX2 with breast cancer risk by estrogen/progesterone receptor status. Mol Carcinog 2013;52 Suppl 1:E52-9.
Chan M, Ji SM, Liaw CS, Yap YS, Law HY, Yoon CS, et al
. Association of common genetic variants with breast cancer risk and clinicopathological characteristics in a Chinese population. Breast Cancer Res Treat 2012;136:209-20.
Chen XH, Li XQ, Chen Y, Feng YM. Risk of aggressive breast cancer in women of Han nationality carrying TGFB1 rs1982073 C allele and FGFR2 rs1219648 G allele in North China. Breast Cancer Res Treat 2011;125:575-82.
Chen F, Lu M, Xue Y, Zhou J, Hu F, Chen X, et al
. Genetic variants of fibroblast growth factor receptor 2 (FGFR2) are associated with breast cancer risk in Chinese women of the Han nationality. Immunogenetics 2012;64:71-6.
Fu F, Wang C, Huang M, Song C, Lin S, Huang H. Polymorphisms in second intron of the FGFR2 gene are associated with the risk of early-onset breast cancer in Chinese Han women. Tohoku J Exp Med 2012;226:221-9.
Fu L, Chen S, Huang HL, Luo WZ, Fan Q. Relationship between polymorphism of fibroblast growth factor receptor 2 rs2981582 and susceptibility of breast cancer. Shandong Med J 2013;53:4-6.
Li X. The breast cancer susceptive locus screening in Han Chinese women and meta-analysis on common breast cancer risk factors. Master Thesis, Southern Medical University (in Chinese); 2011.
Liang J, Chen P, Hu Z, Zhou X, Chen L, Li M, et al
. Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women. Carcinogenesis 2008;29:2341-6.
Liu M, San KR, He Y, Zhang T, Qi XL, Zhao Y, et al
. The relationship between two FGFR2 polymorphism and breast cancer. Chin J Clin Oncol 2009;36:413-6.
Liu M, San KR, He Y, Zhang T, Xiao Y, Wu CX, et al
. The association of FGFR2 rs 1219648 polymorphism with susceptibility of breast cancer in Han population in Guizhou Province. Chin J Clin Oncol 2010;37:29-31.
Liu CL, Hu XP, Guo WD, Yang L, Dang J, Jiao HY. Case-control study on the fibroblast growth factor receptor 2 gene polymorphisms associated with breast cancer in chinese han women. J Breast Cancer 2013;16:366-71.
Ma JP, Cao MZ, Ge YL, Ma ZL, Liu XY. Relative research of FGFR2 gene single nucleotide polymorphism and breast neoplasm. Chin J Curr Adv Gen Surg 2011;14:111-5.
Shen GS, Zhao JD, Geng PL, Dou LJ, Ma DL, Zhang SY, et al
. A study of relationship between FGFR2 gene polymorphisms and dependability of female breast cancer in Han dynasty and Muslim population in Qinghai area. J Qinghai Med Coll 2011;32:222-5.
Wang SM, Chen X, Hu FF, Huang HN, Yu J, Wang K, et al
. Risk of breast cancer in women of Han nationality in Hubei area with the SNP of TNRC9 and FGFR2. Chin J Cancer Prev Treat 2011;18:1749-51.
Xu WH, Wang SB. Relative research of FGFR2 gene SNPs and breast neoplasm. Chin Modern Med 2012;19:17-8.
Xu WH, Wang SB. Relative research of FGFR2 Gene SNPs and breast neoplasm. Chin Med Herald 2012;9:13-5.
Zhang JP, Qian Y, Wang FR, Dong MH, Xu M, Dong J, et al
. Polymorphisms of fibroblast growth factor receptors 2 (FGFR2) and susceptibility of breast cancer. Chin J Dis Control Prev 2010;14:764-7.
Zhao JD, Shen GS, Geng PL, Wang LJ, Cao CZ, He JX, et al
. A study of relationship between FGFR2 rs2981579 gene polymorphism and female breast cancer among Han and Zang populations in Qinghai area. Chin J Clin Lab Sci 2012;30:43-4.
Zhao HM, Zhang B, Yao H, Li XL, Song YQ, Wang X, et al
. Correlations between FGFR2 Gene polymorphism and susceptibility of breast cancer. Chin J Clin Oncol 2010;37:626-9.
Zhou XK, Hua D, Guo ZJ, Huang ZH, Liu Zh, Song MX, et al
. Implication of the FGFR2 rs2981579 polymorphisms in breast cancer in Chinese Han women. Suzhou Univ J Med Sci 2010;30:528-31.
Zhou XK, Li LH, Huag ZH, Liu Zh, Song M ×. A Study of the FGFR2 rs11200014 polymorphisms in Breast Cancer in Chinese Women. J Pract Med 2010;26:3137-319.
Jia C, Cai Y, Ma Y, Fu D. Quantitative assessment of the effect of FGFR2 gene polymorphism on the risk of breast cancer. Breast Cancer Res Treat 2010;124:521-8.
Wang H, Yang Z, Zhang H. Assessing interactions between the associations of fibroblast growth factor receptor 2 common genetic variants and hormone receptor status with breast cancer risk. Breast Cancer Res Treat 2013;137;511-22.
Zhou L, Yao F, Luan H, Wang Y, Dong X, Zhou W, et al
. Three novel functional polymorphisms in the promoter of FGFR2 gene and breast cancer risk: A HuGE review and meta-analysis. Breast Cancer Res Treat 2012;136;885-97.
Zhang J, Qiu LX, Wang ZH, Leaw SJ, Wang BY, Wang JL, et al
. Current evidence on the relationship between three polymorphisms in the FGFR2 gene and breast cancer risk: A meta-analysis. Breast Cancer Res Treat 2010;124;419-24.
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6]